Glaucoma is the second leading cause of blindness in the world. This shows the importance of the work of EyeD Pharma, a company specialising in the ophthalmological sector and based near the University Hospital of Liège, which is developing a revolutionary ocular implant in the fight against this eye disease.
Glaucoma is a degenerative disease of the optic nerve. It causes a progressive loss of vision, starting at the periphery and gradually progressing towards the centre. Until now, the treatment of this disease has required not only medical interventions (laser, surgery) but also a demanding treatment: the daily use of drops.
Hence the interest of EyeD Pharma's ocular implant, which is as small as it is precise and contains and diffuses the treatment without patient intervention. Indeed, this two-hair-sized technology releases an active ingredient over the long term, i.e. two to three years.
The Liège-based company will be able to supply its eye implant worldwide within six years.
